Drug Trial Radar · NCT07880392
Efficacy and Safety of DNN.63.18.040 for the Treatment of Moderate to Severe Pain
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
370
Planned (sponsor's estimate)
Start
Oct 19, 2026
Primary completion
Mar 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Ache Laboratorios Farmaceuticos S.A.Industry
- Sponsor type
- Industry
- First posted
- Oct 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of DNN.63.18.040 compared with Tramal® for the treatment of moderate to severe pain.
Conditions
- Acute Pain
Interventions
Product DNN.63.18.040Drug
One capsule four times daily for 3 days
Tramal®Drug
One capsule four times daily for 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Pain Relief Score (TOTPAR6)Time frame: 6 hours after first dose
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.